Current with legislation from the 2023 Regular and Special Sessions signed by the Governor as of November 21, 2023.
Section 562.009 - Requirements Concerning Selection of Generically Equivalent Drug or Interchangeable Biological Product(a) Before delivery of a prescription for a generically equivalent drug or interchangeable biological product, a pharmacist must personally, or through the pharmacist's agent or employee:(1) inform the patient or the patient's agent that a less expensive generically equivalent drug or interchangeable biological product is available for the brand prescribed; and(2) ask the patient or the patient's agent to choose between the generically equivalent drug or interchangeable biological product and the brand prescribed.(a-1) Repealed by Acts 2015, 84th Leg., R.S., Ch. 599 , Sec. 14(2), eff. September 1, 2015.(b) A pharmacy is not required to comply with the provisions of Subsection (a): (1) in the case of the refill of a prescription for which the pharmacy previously complied with Subsection (a) with respect to the same patient or patient's agent; or(2) if the patient's physician or physician's agent advises the pharmacy that: (A) the physician has informed the patient or the patient's agent that a less expensive generically equivalent drug or interchangeable biological product is available for the brand prescribed; and(B) the patient or the patient's agent has chosen either the brand prescribed or the less expensive generically equivalent drug or interchangeable biological product.(c) A pharmacy that supplies a prescription by mail is considered to have complied with the provisions of Subsection (a) if the pharmacy includes on the prescription order form completed by the patient or the patient's agent language that clearly and conspicuously:(1) states that if a less expensive generically equivalent drug or interchangeable biological product is available for the brand prescribed, the patient or the patient's agent may choose between the generically equivalent drug or interchangeable biological product and the brand prescribed; and(2) allows the patient or the patient's agent to indicate the choice between the generically equivalent drug or interchangeable biological product and the brand prescribed.(d) If the patient or the patient's agent fails to indicate otherwise to a pharmacy on the prescription order form under Subsection (c), the pharmacy may dispense a generically equivalent drug or interchangeable biological product.(e) If the prescription is for an immunosuppressant drug, as defined by Section 562.0141(a)(1), the pharmacist must comply with the provisions of Section 562.0141. This subsection expires if Section 562.0141 expires under the requirements of Section 562.0142.Amended by Acts 2015, Texas Acts of the 84th Leg. - Regular Session, ch. 1007,Sec. 8, eff. 9/1/2015.Amended by Acts 2015, Texas Acts of the 84th Leg. - Regular Session, ch. 1007,Sec. 9, eff. 9/1/2015.Amended by Acts 2015, Texas Acts of the 84th Leg. - Regular Session, ch. 599,Sec. 14, eff. 9/1/2015.Amended By Acts 2007, 80th Leg., R.S., Ch. 385, Sec. 3, eff. 6/15/2007.Amended By Acts 2005, 79th Leg., Ch. 943, Sec. 2, eff. 9/1/2005.Amended By Acts 2005, 79th Leg., Ch. 943, Sec. 3, eff. 9/1/2005.Amended By Acts 2005, 79th Leg., Ch. 943, Sec. 4, eff. 9/1/2005.Amended By Acts 2005, 79th Leg., Ch. 943, Sec. 5, eff. 9/1/2005. Acts 1999, 76th Leg., ch. 388, Sec. 1, eff. 9/1/1999.